Target market: Orphan drug indications in pediatric cancers
Few rare patient populations are as vulnerable and in need of advocacy as children with cancer. Pharmaceutical companies face many disincentives to pursue pediatric oncology therapeutics, including low incidence, high costs of conducting pediatric trials, and a lack of funding for early-stage research. Artisan is leveraging the deep preclinical domain expertise of cc-TDI to reverse the 40+ year drought represented by only 8 drug approvals for pediatric cancer. To achieve this goal, we aim to have 5 new compounds reach the clinic annually for children with high risk cancers.
